News: Optimer Pharmaceuticals Inc (OPTR.OQ)

OPTR.OQ on NASDAQ Stock Exchange Global Select Market

12.48USD
1 Aug 2013
Price Change (% chg)

$-0.03 (-0.24%)
Prev Close
$12.51
Open
$12.64
Day's High
$12.65
Day's Low
$12.48
Volume
558,582
Avg. Vol
327,918
52-wk High
$16.77
52-wk Low
$8.66

Search Stocks
Select another date:

Tue, Jul 30 2013

Cubist to pay up to $1.6 billion for two antibiotics makers

- Cubist Pharmaceuticals Inc has agreed to pay up to $1.6 billion for Trius Therapeutics Inc and Optimer Pharmaceuticals Inc, expanding its heft in antibiotics at a time when the number of drug-resistant viruses are on the rise.

UPDATE 2-Cubist to pay up to $1.6 bln for two antibiotics makers

* Cubist sees the sum of both deals to be accretive in 2015

Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 billion

- Cubist Pharmaceuticals Inc said it would buy Trius Therapeutics Inc and Optimer Pharmaceuticals Inc for up to $1.62 billion to boost its antibiotics portfolio.

CORRECTED-Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 bln

(Corrects paragraphs 2 and 3 to say the per-share offers include contingency payments)

Cubist bid for Optimer before sale process began: sources

NEW YORK - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told Reuters on Wednesday.

Cubist bid almost $1 bln for Optimer before sale process-sources

NEW YORK, May 15 - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told Reuters on Wednesday.

Optimer shares rise after report names Glaxo, Cubist as potential buyers

- Shares of Optimer Pharmaceuticals Inc rose as much as 24 percent after a Bloomberg report said GlaxoSmithKline Plc and Cubist Pharmaceuticals Inc were among those interested in buying the antibiotic maker.

UPDATE 1-Optimer shares rise after report names Glaxo, Cubist as potential buyers

* Shares up 18 pct (Adds comments from an analyst, details)

Optimer Pharma exploring sale, shares jump

- Drugmaker Optimer Pharmaceuticals Inc said it was exploring a sale and replaced its chief executive as part of a review of compliance issues, sending its shares up 19 percent.

Optimer Pharma exploring sale, shares jump

- Optimer Pharmaceuticals Inc said it was exploring a possible sale of the company among a full range of alternatives and that Chairman Henry McKinnell would act as chief executive for the duration of the review process.

Select another date:
Search Stocks